Ligand Pharmaceuticals Inc
NASDAQ:LGND
Ligand Pharmaceuticals Inc
Net Income (Common)
Ligand Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ligand Pharmaceuticals Inc
NASDAQ:LGND
|
Net Income (Common)
$52.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-18%
|
CAGR 10-Years
16%
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Ligand Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
52.2m
USD
Based on the financial report for Dec 31, 2023, Ligand Pharmaceuticals Inc's Net Income (Common) amounts to 52.2m USD.
What is Ligand Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
16%